PhRMA: Part D Premium Projections Repudiate PCMA's Warning Sovaldi Would Hike Seniors' Costs

By John Wilkerson / August 1, 2014 at 2:52 PM
Brand drug makers asserted Friday (Aug. 1) that CMS' projection of stable Part D premiums next year show that complaints about Sovaldi's price are much ado about nothing; but the drug plans and pharmacy benefit managers that had warned the hepatitis C drug would drive up premiums say the latest projections are merely an example of insurers doing a good job of controlling costs, and a key drug price control advocate said premiums likely would have fallen were it not...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.